EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
May 08, 2023 16:01 ET
|
EQRx, Inc.
Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated...
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
April 27, 2023 08:00 ET
|
EQRx, Inc.
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of...
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
February 23, 2023 07:00 ET
|
EQRx, Inc.
For Investors Lerociclib: Ongoing Phase 2 trial in first- and second-line treatment of metastatic breast cancer; expect to initiate Phase 3 trial in advanced endometrial cancer in 1H 2023 ...
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 08:00 ET
|
EQRx, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of...
EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer
December 19, 2022 08:00 ET
|
EQRx, Inc.
Application is based on data from the pivotal Phase 3 GEMSTONE-302 trial assessing sugemalimab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung...
EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
December 02, 2022 08:00 ET
|
EQRx, Inc.
Submission is EQRx’s first to European Medicines AgencyApplication is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated...
EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
November 10, 2022 07:00 ET
|
EQRx, Inc.
Aumolertinib: Clarity on path for potential U.S. approval; continue to pursue ex-U.S. approvals based on existing data, with MAA under review by U.K.’s MHRASugemalimab: Based on recent FDA feedback,...
EQRx to Participate in the Jefferies 2022 London Healthcare Conference
November 07, 2022 08:00 ET
|
EQRx, Inc.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...
EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022
October 28, 2022 08:00 ET
|
EQRx, Inc.
CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...
EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
August 11, 2022 07:00 ET
|
EQRx, Inc.
Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLCAnnounced U.K. MHRA acceptance of EQRx’s first regulatory submission...